Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Lenalidomide-RCHOP and R-HIDAC in Untreated Mantle Cell Lymphoma
NCT02633137Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2015
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in mantle cell lymphoma (MCL), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2015; status: completed.
02
Drugs
lenalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02633137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633137.